AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32013994 — intervention group
Group type: EXPERIMENTAL
Intervention: Modelled geographical access (P) using GIS tools (ArcGIS)
Number of subjects: 0
Study 32013994 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported travel times (R)
Number of subjects: 0
Study 32013994 — intervention group
Group type: EXPERIMENTAL
Intervention: Modelled travel times to the actual facilities accessed (A)
Number of subjects: 0
Study 32013996 — intervention group
Group type: EXPERIMENTAL
Intervention: Moves app
Number of subjects: 274
Study 32013996 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey responses
Number of subjects: 274
Study 32013998 — intervention group
Group type: EXPERIMENTAL
Intervention: MOCO cines
Number of subjects: 149
Study 32014005 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear wave ultrasound elastography (SWE)
Number of subjects: 560
Study 32014041 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-traumatic cerebral infarction (PTCI)
Number of subjects: 143
Study 32014041 — intervention group
Group type: COMPARATOR
Intervention: IMPACT core model without PTCI
Number of subjects: 143
Study 32014041 — intervention group
Group type: COMPARATOR
Intervention: IMPACT extended model without PTCI
Number of subjects: 143
Study 32014287 — intervention group
Group type: EXPERIMENTAL
Intervention: Zenith Alpha thoracic endovascular graft (Cook Medical)
Number of subjects: 50
Study 32014432 — intervention group
Group type: EXPERIMENTAL
Intervention: PROGALIAM (2006-2013)
Number of subjects: 6783
Study 32014432 — intervention group
Group type: COMPARATOR
Intervention: Pre-PROGALIAM (2001-2005)
Number of subjects: 6783
Study 32014871 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of PLH children
Number of subjects: 77
Study 32015000 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with newly identified mutations in MCPH
Number of subjects: 7
Study 32015090 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rt-PA
Number of subjects: 944
Study 32015419 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0
Study 32015419 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of tolvaptan and pioglitazone
Number of subjects: 0
Study 32015419 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 32015566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac valve surgery with infective endocarditis (IE)
Number of subjects: 40
Study 32015566 — intervention group
Group type: COMPARATOR
Intervention: Cardiac valve surgery without infective endocarditis (control)
Number of subjects: 40
Study 32016127 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) for 3 years
Number of subjects: 143
Study 32016390 — intervention group
Group type: EXPERIMENTAL
Intervention: MRDTI negative for DVT
Number of subjects: 305
Study 32016390 — intervention group
Group type: EXPERIMENTAL
Intervention: MRDTI readings
Number of subjects: 305
Study 32016415 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 42
Study 32016415 — intervention group
Group type: EXPERIMENTAL
Intervention: SG
Number of subjects: 42
Study 32016427 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH in early postmenarchal girls (5.2 ± 0.3 ng/mL)
Number of subjects: 23
Study 32016427 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH in girls with ovulatory cycles
Number of subjects: 23
Study 32016427 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of AMH with ln_LH
Number of subjects: 23
Study 32016427 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of AMH with ln_androstenedione
Number of subjects: 23
Study 32016427 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of AMH with ln_testosterone
Number of subjects: 23
Study 32016427 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of AMH with ovarian volume
Number of subjects: 23
Study 32016427 — intervention group
Group type: COMPARATOR
Intervention: Correlation of AMH in women with estradiol
Number of subjects: 23
Study 32016427 — intervention group
Group type: COMPARATOR
Intervention: Correlation of AMH in women with P4
Number of subjects: 23
Study 32016528 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol group (Group Pro)
Number of subjects: 35
Study 32016643 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary questionnaire for caffeine intake estimation
Number of subjects: 91
Study 32016643 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h urinary excretion measurement
Number of subjects: 91
Study 32016643 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis between self-reported intake and urinary excretion
Number of subjects: 91
Study 32016676 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CXCL10 expression
Number of subjects: 3763
Study 32016676 — intervention group
Group type: EXPERIMENTAL
Intervention: Downregulated CXCL10 expression
Number of subjects: 3763
Study 32017044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 2233
Study 32017341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulimorelin 600-1200 µg/kg
Number of subjects: 0
Study 32017341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulimorelin 150-600 µg/kg
Number of subjects: 0
Study 32017433 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized appropriate medical therapy (AMT)
Number of subjects: 39
Study 32017652 — intervention group
Group type: EXPERIMENTAL
Intervention: ctHPVDNA surveillance
Number of subjects: 115
Study 32017652 — intervention group
Group type: EXPERIMENTAL
Intervention: ctHPVDNA positivity in two consecutive plasma samples
Number of subjects: 115
Study 32019278 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-Taxane-Based Neoadjuvant Chemotherapy
Number of subjects: 92
Study 32019278 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-containing treatment
Number of subjects: 92
Study 32019278 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 92
Study 32019333 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal linkage to care after intervention
Number of subjects: 87
Study 32019333 — intervention group
Group type: COMPARATOR
Intervention: Paternal testing for HIV
Number of subjects: 87
Study 32019333 — intervention group
Group type: COMPARATOR
Intervention: Paternal linkage to care
Number of subjects: 87
Study 32019333 — intervention group
Group type: COMPARATOR
Intervention: Paternal on ART
Number of subjects: 87
Study 32019508 — intervention group
Group type: EXPERIMENTAL
Intervention: Minneapolis stores post-policy compliance measures
Number of subjects: 155
Study 32019508 — intervention group
Group type: COMPARATOR
Intervention: St. Paul stores post-policy compliance measures
Number of subjects: 155
Study 32019508 — intervention group
Group type: EXPERIMENTAL
Intervention: Corporate stores in Minneapolis
Number of subjects: 155
Study 32019508 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood characteristics in compliance measures
Number of subjects: 155
Study 32019538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic areas (CCAM)
Number of subjects: 11
Study 32019538 — intervention group
Group type: COMPARATOR
Intervention: Control areas
Number of subjects: 11
Study 32019550 — intervention group
Group type: EXPERIMENTAL
Intervention: MO with OSA without CPAP
Number of subjects: 45
Study 32019550 — intervention group
Group type: EXPERIMENTAL
Intervention: MO with OSA and CPAP
Number of subjects: 45
Study 32019550 — intervention group
Group type: EXPERIMENTAL
Intervention: MO without OSA
Number of subjects: 45
Study 32019550 — intervention group
Group type: COMPARATOR
Intervention: Control group (participants in the EPIOSA study)
Number of subjects: 45
Study 32019577 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological test battery (six tests)
Number of subjects: 45
Study 32019596 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% Silver Diamine Fluoride (SDF) solution
Number of subjects: 730
Study 32019596 — intervention group
Group type: COMPARATOR
Intervention: 5% Sodium Fluoride (NaF) varnish
Number of subjects: 730
Study 32019635 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist training in positive behaviour support (PBS)
Number of subjects: 246
Study 32019635 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 246
Study 32020437 — intervention group
Group type: EXPERIMENTAL
Intervention: RO6839921 (inactive pegylated prodrug of idasanutlin) administered at doses of 120-300 mg, with maximum tolerated dose (MTD) identified as 200 mg.
Number of subjects: 26
Study 32020437 — intervention group
Group type: EXPERIMENTAL
Intervention: RO6839921 (inactive pegylated prodrug of idasanutlin) administered at doses of 120-300 mg.
Number of subjects: 26
Study 32020889 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 282
Study 32020889 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture (SA)
Number of subjects: 282
Study 32020889 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin
Number of subjects: 282
Study 32021066 — intervention group
Group type: EXPERIMENTAL
Intervention: Baerveldt-350 glaucoma implant (BGI)
Number of subjects: 81
Study 32021066 — intervention group
Group type: COMPARATOR
Intervention: Ahmed glaucoma implant (AGV-S2 and FP7 models)
Number of subjects: 81
Study 32021070 — intervention group
Group type: EXPERIMENTAL
Intervention: iStent inject implantation
Number of subjects: 57
Study 32021227 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 0
Study 32021227 — intervention group
Group type: COMPARATOR
Intervention: enalapril
Number of subjects: 0
Study 32021387 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose manual acupuncture (MAL)
Number of subjects: 57
Study 32021387 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose manual acupuncture (MAH)
Number of subjects: 57
Study 32021407 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 353
Study 32021407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study 32021411 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam IV 30 mg
Number of subjects: 379
Study 32021411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study 32021913 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (Transiderm-Nitro 5 patch) during radiotherapy
Number of subjects: 42
Study 32022390 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI intervention
Number of subjects: 2160
Study 32022390 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI futility risk model
Number of subjects: 2160
Study 32022437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric sized supraglottic airways designed for intubation
Number of subjects: 0
Study 32022437 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy and combination techniques for intubation
Number of subjects: 0
Study 32022437 — intervention group
Group type: EXPERIMENTAL
Intervention: Techniques for maintaining oxygenation during intubation
Number of subjects: 0
Study 32022437 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway management techniques in patients at risk for aspiration
Number of subjects: 0
Study 32022437 — intervention group
Group type: EXPERIMENTAL
Intervention: Considerations in cannot intubate cannot oxygenate scenarios
Number of subjects: 0
Study 32022621 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)
Number of subjects: 0
Study 32022692 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy program (Breathe)
Number of subjects: 536
Study 32022692 — intervention group
Group type: COMPARATOR
Intervention: Anxiety-based resource webpages (control)
Number of subjects: 536
Study 32022692 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathe respondents' perceived change in anxiety
Number of subjects: 536
Study 32022781 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth platform for nutrition interventions
Number of subjects: 21
Study 32023303 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care
Number of subjects: 20
Study 32023303 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration
Number of subjects: 20
Study 32023303 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to collaboration
Number of subjects: 20
Study 32023303 — intervention group
Group type: EXPERIMENTAL
Intervention: Needs for stepped care
Number of subjects: 20
Study 32023374 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-mismatched anti-CD19 CAR-NK cells derived from cord blood
Number of subjects: 11
Study 32024079 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiome of RTRs
Number of subjects: 139
Study 32024079 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 139
Study 32024468 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphisms (SNPs) in SCN9A, SCN10A, and SCN11A
Number of subjects: 198
Study 32024471 — intervention group
Group type: EXPERIMENTAL
Intervention: Not taking statins
Number of subjects: 1127
Study 32024471 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 1127
Study 32024471 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral artery disease
Number of subjects: 1127
Study 32024471 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney failure
Number of subjects: 1127
Study 32024471 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smoking
Number of subjects: 1127
Study 32024471 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Hospital Anxiety and Depression Scale-Depression subscale score
Number of subjects: 1127
Study 32024471 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventable and potentially modifiable factors
Number of subjects: 1127
Study 32024471 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking, low physical activity, not taking statins, not participating in cardiac rehabilitation, diabetes
Number of subjects: 1127
Study 32024473 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=1500)
Number of subjects: 2000
Study 32024473 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=500)
Number of subjects: 2000
Study 32024528 — intervention group
Group type: EXPERIMENTAL
Intervention: Equilibrium method
Number of subjects: 34
Study 32024528 — intervention group
Group type: EXPERIMENTAL
Intervention: Average method
Number of subjects: 34
Study 32024528 — intervention group
Group type: EXPERIMENTAL
Intervention: Full method
Number of subjects: 34
Study 32024528 — intervention group
Group type: COMPARATOR
Intervention: No compensation reference
Number of subjects: 34
Study 32024586 — intervention group
Group type: EXPERIMENTAL
Intervention: MATRx plus home sleep apnea test (HSAT)
Number of subjects: 0
Study 32024586 — intervention group
Group type: EXPERIMENTAL
Intervention: MATRx plus HSAT
Number of subjects: 0
Study 32024675 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity MR biomarkers (muscle fat fraction and MRI T2)
Number of subjects: 160
Study 32024675 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity MR biomarkers from proximal muscles
Number of subjects: 160
Study 32024786 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent menstrual health management (MHM) intervention including teacher training, menstrual kit use, pain management, drama skit, provision of analgesics, and improvements to school facilities.
Number of subjects: 450
Study 32024786 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent menstrual health management (MHM) intervention.
Number of subjects: 450
Study 32025570 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate and dihydroartemisinin
Number of subjects: 0
Study 32025589 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.05%
Number of subjects: 4
Study 32025615 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea Hull Fiber (PHF)
Number of subjects: 0
Study 32025615 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 32025629 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 20
Study 32025629 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 20
Study 32025629 — intervention group
Group type: COMPARATOR
Intervention: Control (native joints and OJA)
Number of subjects: 20
Study 32025741 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA treatment (shoulder injections)
Number of subjects: 140
Study 32025741 — intervention group
Group type: COMPARATOR
Intervention: No shoulder treatment (control group)
Number of subjects: 140
Study 32025755 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary C-C motif chemokine ligand 14 (CCL14)
Number of subjects: 364
Study 32025755 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary KIM-1
Number of subjects: 364
Study 32025755 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cystatin C
Number of subjects: 364
Study 32025755 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary NGAL
Number of subjects: 364
Study 32025764 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin-soaked grafts (Group 2)
Number of subjects: 1674
Study 32025764 — intervention group
Group type: COMPARATOR
Intervention: No vancomycin (Group 1)
Number of subjects: 1674
Study 32025764 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1674
Study 32026092 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management Condition (CMC)
Number of subjects: 16
Study 32026092 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Condition (UCC)
Number of subjects: 16
Study 32026120 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Deep Vein Arterialization (pDVA) using LimFlow System
Number of subjects: 50
Study 32026243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone, administered in three divided doses daily, median dose 2400 mg/day, exposure duration median 3.0 years.
Number of subjects: 83
Study 32026327 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic PET/CTA myocardial blood flow assessment with fused imagery (DEMYSTIFY)
Number of subjects: 108
Study 32026347 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone, mean (SD) daily dose 2058.7 (399.2) mg, mean (SD) exposure 22.8 (9.6) weeks
Number of subjects: 1620
Study 32026407 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg plus pirfenidone 2403 mg/day once daily
Number of subjects: 21
Study 32026407 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study 32026411 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol 20 mg hard-boiled lozenges
Number of subjects: 390
Study 32026411 — intervention group
Group type: COMPARATOR
Intervention: Placebo hard-boiled lozenges
Number of subjects: 390
Study 32026446 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation for acute stroke patients
Number of subjects: 0
Study 32026446 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisions to withhold or withdraw care
Number of subjects: 0
Study 32026446 — intervention group
Group type: EXPERIMENTAL
Intervention: mRS scores at 3 and 6 months
Number of subjects: 0
Study 32026446 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life at 1 year
Number of subjects: 0
Study 32026743 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient reports of pain interference
Number of subjects: 0
Study 32026743 — intervention group
Group type: COMPARATOR
Intervention: Informal caregiver proxy reports of pain interference
Number of subjects: 0
Study 32026814 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial assessment (<72 hours)
Number of subjects: 121
Study 32026814 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up (8-10 weeks)
Number of subjects: 121
Study 32026814 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue palpation and Neer's Test
Number of subjects: 121
Study 32026814 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy interventions
Number of subjects: 121
Study 32026830 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training and localised training for upper and lower limbs conducted for 24 sessions, three times per week
Number of subjects: 77
Study 32027796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 1373
Study 32027796 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1373
Study 32027796 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 1373
Study 32027796 — intervention group
Group type: COMPARATOR
Intervention: Non-probucol
Number of subjects: 1373
Study 32027796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol and Probucol
Number of subjects: 1373
Study 32027846 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg plus savolitinib 600 mg daily (part B)
Number of subjects: 186
Study 32027846 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg plus savolitinib 300 mg daily (part D)
Number of subjects: 186
Study 32027845 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32027858 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST score (FibroScan-AST) using LSM, CAP, and AST
Number of subjects: 350
Study 32027858 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST score (FibroScan-AST) in external validation cohorts
Number of subjects: 350
Study 32028209 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks until progression or unacceptable toxicity
Number of subjects: 811
Study 32028493 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetoscopic tracheal balloon occlusion
Number of subjects: 14
Study 32028493 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 14
Study 32028493 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocolytics
Number of subjects: 14
Study 32028493 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal pessary placement
Number of subjects: 14
Study 32028493 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioreduction
Number of subjects: 14
Study 32028493 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age at birth
Number of subjects: 14
Study 32028493 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency ventilation
Number of subjects: 14
Study 32028493 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation
Number of subjects: 14